Blockchain Registration Transaction Record

Oncotelic's 20nm Nanoparticle Tech Boosts Cancer Drug Delivery to 100%

Oncotelic Therapeutics begins Phase 1 trial for Sapu003 using 20nm nanoparticle technology that achieves 100% bioavailability for breast cancer drug delivery, revolutionizing targeted treatment.

This development matters because it addresses one of the most persistent challenges in cancer treatment: delivering therapeutic agents effectively to tumors while minimizing damage to healthy tissues. Current oral cancer medications often have poor bioavailability, meaning patients receive only a fraction of the intended dose while experiencing significant side effects. Oncotelic's nanoparticle technology achieving 100% bioavailability could dramatically improve treatment efficacy and reduce adverse effects, potentially transforming patient outcomes. For the millions affected by breast cancer worldwide, this represents hope for more effective, targeted therapies that could extend survival and improve quality of life during treatment. The accelerated development platform also means these innovations could reach patients faster than traditional drug development timelines would allow.